close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MacroGenics, Inc.

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of First Quarter 2025 Financial Results
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Leadership Transition
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Provides Vobramitamab Duocarmazine Update
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Tickers MGNX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today